Bristol-Myers Squibb Affirms FY2026 Adj EPS Guidance of $6.05-$6.35 vs $6.27 Est; Affirms FY2026 Sales Guidance of $46.000B-$47.500B vs $47.105B Est

Benzinga Newsdesk www.benzinga.com Negative 63.8%

Neg 63.8% Neu 0% Pos 0%

Bristol-Myers Squibb (NYSE:BMY) affirms FY2026 Adj EPS guidance from $6.05-$6.35 to $6.05-$6.35 vs $6.27 analyst estimate. Affirms FY2026 sales outlook from $46.000 billion-$47.500 billion to $46.000 billion-$47.500 billion vs $47.105 billion estimate.